HOLD; stage adds in $135-$140 zone; protect existing gains at $138

• RSI 74 + 1.024x upper Bollinger tag + 9.4% above 20-day VWMA together signal overbought exhaustion risk
• Stock literally mean-reverted from $129 to $147 over 18 sessions—same pattern can reverse on any catalyst (earnings miss, oil spike, pipeline negative)
• Aggressive tiered add plan ($147.60 / $139 / close above $149) yields average entry ~$145 with negative asymmetry: $13.30 downside (~9.2%) vs $12 upside (~8.3%)
• Conservative entry zone $135-$140 offers 2:1 to 3:1 asymmetry: $17-$22 upside to $157 target vs $3-$8 downside to $131.70 stop
• Valuation not cheap: Forward P/E 14.92 on forward earnings already capitalized, PEG 2.14 elevated, P/B 15.48 high, stock at 76% of 52-week range
• Healthcare sector up 22% in 6 months, beating S&P by 11 percentage points—this is a mean-reversion risk, not a buy signal
• Yeztugo PrEP one-quarter data insufficient to declare structural inflection; HIV franchise maturity flagged as top-line growth limiter
• Biktarvy legal win largely priced in over $129-to-$147 rally; not a fresh catalyst
• Existing position at $138 is up ~7%; protect gains with disciplined stop rather than adding into overbought conditions
• At 0.336 beta with 14% run in 18 sessions, any macro catalyst triggers 5-10% pullback

→ vs aggressive: RSI 74 alone is survivorship bias—aggressive analyst remembers the 65-80 uptrends that continued but forgets the names that tagged 74, stayed elevated one week, and mean-reverted 5-10%

→ vs aggressive: Upper Bollinger tag described as 'parabolic in feel' within the bullish technical framework itself—the report acknowledges 'price needs to consolidate while VWMA catches up'

→ vs aggressive: 'Wait for $135 pullback is a fantasy' is empirically wrong—GILD was literally at $129.31 in late July and $137.77 six months ago; mean reversion isn't fantasy, it's what just happened in reverse

→ vs aggressive: Absence of immediate catalyst doesn't mean no pullback will come—earnings miss, Hormuz oil spike, or pipeline negative all trigger 5-10% pullback in a 0.336 beta name

→ vs aggressive: Forward P/E 14.92 sounds cheap only if ignoring that it's on forward earnings already capitalized into price; trailing P/E is impaired, PEG 2.14 is elevated, P/B 15.48 is high

→ vs aggressive: Healthcare as defensive leadership is itself a rotation risk—if sentiment shifts (Hormuz resolution, AI narrative), defensives that already rallied get hit first and hardest

→ vs aggressive: Yeztugo one-quarter ramp doesn't make an inflection—HIV franchise maturity flagged as top-line limiter; need 2-3-4 quarters of sustained data

→ vs aggressive: Biktarvy legal moat is priced in—stock moved 14% from $129 to $147 while news was landing; no discount to legal durability remains

HOLD with modified execution

• Three momentum gauges converging (RSI 74, 1.024x upper Bollinger tag, price 9.4% above VWMA) signals a regime change rather than noise
• First add zone should be $139 to $142, not $135 (conservative) or $147.60 (aggressive); 10-EMA at $139.04 is natural first support
• From $140 entry with $131.70 stop: $17 upside to $157 target vs $8.30 downside = 2.05:1 risk-reward, meeting conservative threshold
• Second add trigger: close above $148.97 (August 19 intraday high) with above-average volume
• Aggressive tiered plan with 1/3 at $147.60 averaging $145 results in approximately 1:1 risk-reward, not the -1.7:1 conservative calculation but still not optimal
• Yeztugo PrEP sales doubled YoY (100% growth rate on billion-dollar-plus base) warrants higher evidence threshold than conservative analyst applies
• Legal patent win requires quarters, not sessions, to fully capitalize into valuation
• Core management question: existing position at $138 with 7% gain; risk is overcommitting capital at stretched entry rather than missing upside

→ vs aggressive: RSI 74 + Bollinger + VWMA convergence is a regime signal, not dismissible noise; three different momentum frameworks flashing simultaneously demands acknowledgment

→ vs aggressive: Forward P/E 14.92 alone does not constitute 'cheap' when P/B is 15.48, PEG is 2.14, and stock trades at 76% of 52-week range; selection bias to anchor on one supporting metric

→ vs aggressive: Close below upper Bollinger band on next session with meaningful volume entirely invalidates the breakout interpretation; adding at the tag creates asymmetric drawdown risk

→ vs conservative: '$135 to $140' framework too wide and too patient; 10-EMA at $139 is more realistic support level; waiting for $135 would have missed GILD rally from $129 to $147 in 18 sessions

→ vs conservative: Yezdogo PrEP doubling YoY (100% growth) is not 'just one print'; YoY doublings on billion-dollar-plus base typically don't reverse in one quarter

→ vs conservative: Legal win being 'largely priced in' assumes perfect market efficiency; patent moats typically take quarters, not sessions, to fully capitalize